argenx SE（ARGX）财务数据ARGXargenx SE

argenx SE (ARGX) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Research and Development Service Fees (FTE), accounting for 45.4% of total sales, equivalent to $142.63K. Other significant revenue streams include Milestone Payments and Upfront Payments. Understanding this composition is critical for investors evaluating how ARGX navigates market cycles within the Biotechnology & Medical Research industry.

Evaluating the bottom line, argenx SE maintains a gross margin of 90.43%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at 32.54%, while the net margin is 31.22%. These profitability ratios, combined with a Return on Equity (ROE) of 23.64%, provide a clear picture of how effectively ARGX converts its operational activities into shareholder value.

In the context of the broader market, ARGX competes directly with industry leaders such as MRNA and NTRA. With a market capitalization of $53.26B, it holds a leading position in the sector. When comparing efficiency, ARGX's gross margin of 90.43% stands against MRNA's 64.14% and NTRA's 63.70%. Such benchmarking helps identify whether argenx SE is trading at a premium or discount relative to its financial performance.

Argenx has demonstrated robust revenue growth, with Q2 2026 revenue reaching $1.515 billion, up from $1.128 billion in Q3 2025. The gross margin remains strong at 90.43%, reflecting efficient operations.